BR112017020591A2 - análogo de trifluoroetila específico para uso no tratamento de síndrome de sjögren - Google Patents

análogo de trifluoroetila específico para uso no tratamento de síndrome de sjögren

Info

Publication number
BR112017020591A2
BR112017020591A2 BR112017020591-2A BR112017020591A BR112017020591A2 BR 112017020591 A2 BR112017020591 A2 BR 112017020591A2 BR 112017020591 A BR112017020591 A BR 112017020591A BR 112017020591 A2 BR112017020591 A2 BR 112017020591A2
Authority
BR
Brazil
Prior art keywords
sjögren
trifluoroethyl
syndrome
analogue
treatment
Prior art date
Application number
BR112017020591-2A
Other languages
English (en)
Other versions
BR112017020591B1 (pt
BR112017020591B8 (pt
Inventor
Anthony Allen Rodger
Barone Francesca
Anthony Fahy William
Nayar Saba
Original Assignee
Ucb Biopharma Sprl
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ucb Biopharma Sprl filed Critical Ucb Biopharma Sprl
Publication of BR112017020591A2 publication Critical patent/BR112017020591A2/pt
Publication of BR112017020591B1 publication Critical patent/BR112017020591B1/pt
Publication of BR112017020591B8 publication Critical patent/BR112017020591B8/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/472—Non-condensed isoquinolines, e.g. papaverine
    • A61K31/4725—Non-condensed isoquinolines, e.g. papaverine containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0031—Rectum, anus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/006—Oral mucosa, e.g. mucoadhesive forms, sublingual droplets; Buccal patches or films; Buccal sprays
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • Ophthalmology & Optometry (AREA)
  • Otolaryngology (AREA)
  • Pulmonology (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

n-{(r)-1-[8-cloro-2-(1-oxipiridin-3-il)-quinolin-3-il]-2,2,2-trifluoroetil}-pirido[3,2-d]pirimidin-4-ilamina é eficaz no tratamento e/ou na prevenção da síndrome de sjögren.
BR112017020591A 2015-04-21 2016-04-20 Uso de n-{(r)-1-[8-cloro-2-(1-oxipiridin-3-il)quinolin-3-il]-2,2,2-trifluoroetil}pirido[3,2-d]pirimidin-4-ilamina BR112017020591B8 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB1506786.1A GB201506786D0 (en) 2015-04-21 2015-04-21 Therapeutic use
GB1506786.1 2015-04-21
PCT/EP2016/058810 WO2016170014A1 (en) 2015-04-21 2016-04-20 A specific trifluoroethyl quinoline analogue for use in the treatment of sjögren's syndrome

Publications (3)

Publication Number Publication Date
BR112017020591A2 true BR112017020591A2 (pt) 2018-07-03
BR112017020591B1 BR112017020591B1 (pt) 2023-02-07
BR112017020591B8 BR112017020591B8 (pt) 2023-05-16

Family

ID=53298950

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112017020591A BR112017020591B8 (pt) 2015-04-21 2016-04-20 Uso de n-{(r)-1-[8-cloro-2-(1-oxipiridin-3-il)quinolin-3-il]-2,2,2-trifluoroetil}pirido[3,2-d]pirimidin-4-ilamina

Country Status (27)

Country Link
US (1) US10493074B2 (pt)
EP (1) EP3285772B1 (pt)
JP (1) JP6721606B2 (pt)
KR (1) KR102627370B1 (pt)
CN (1) CN107530344B (pt)
AR (1) AR105552A1 (pt)
AU (1) AU2016251236B2 (pt)
BR (1) BR112017020591B8 (pt)
CA (1) CA2981631C (pt)
CL (1) CL2017002669A1 (pt)
CO (1) CO2017010573A2 (pt)
CY (1) CY1122572T1 (pt)
DK (1) DK3285772T3 (pt)
EA (1) EA032432B1 (pt)
ES (1) ES2763335T3 (pt)
GB (1) GB201506786D0 (pt)
HR (1) HRP20192273T1 (pt)
HU (1) HUE047162T2 (pt)
IL (1) IL254766B (pt)
LT (1) LT3285772T (pt)
MX (1) MX2017013148A (pt)
MY (1) MY192972A (pt)
PL (1) PL3285772T3 (pt)
PT (1) PT3285772T (pt)
SG (1) SG11201707789YA (pt)
SI (1) SI3285772T1 (pt)
WO (1) WO2016170014A1 (pt)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201708856D0 (en) 2017-06-02 2017-07-19 Ucb Biopharma Sprl Seletalisib crystalline forms

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2566609C (en) * 2004-05-13 2012-06-26 Icos Corporation Quinazolinones as inhibitors of human phosphatidylinositol 3-kinase delta
ES2563458T3 (es) * 2007-03-23 2016-03-15 Amgen Inc. Compuestos heterocíclicos y sus usos
CN105801550B (zh) * 2009-11-05 2019-06-14 理森制药股份公司 新型苯并吡喃激酶调节剂
UA112517C2 (uk) * 2010-07-06 2016-09-26 Новартіс Аг Тетрагідропіридопіримідинові похідні
AR082799A1 (es) * 2010-09-08 2013-01-09 Ucb Pharma Sa Derivados de quinolina y quinoxalina como inhibidores de quinasa
SI3008053T1 (en) * 2013-06-14 2018-06-29 Gilead Calistoga Llc PHOSPHATIDYLINOSITOL 3-KINATE INHIBITORS

Also Published As

Publication number Publication date
AU2016251236B2 (en) 2018-06-14
MX2017013148A (es) 2018-02-21
LT3285772T (lt) 2020-01-10
AU2016251236A1 (en) 2017-11-09
JP2018513862A (ja) 2018-05-31
HRP20192273T1 (hr) 2020-03-06
MY192972A (en) 2022-09-20
SI3285772T1 (sl) 2020-02-28
GB201506786D0 (en) 2015-06-03
BR112017020591B1 (pt) 2023-02-07
EA201792318A1 (ru) 2018-05-31
KR20170140245A (ko) 2017-12-20
CL2017002669A1 (es) 2018-05-11
DK3285772T3 (da) 2020-01-13
CN107530344A (zh) 2018-01-02
EA032432B1 (ru) 2019-05-31
JP6721606B2 (ja) 2020-07-15
US20180092921A1 (en) 2018-04-05
KR102627370B1 (ko) 2024-01-18
IL254766A0 (en) 2017-12-31
IL254766B (en) 2020-05-31
CY1122572T1 (el) 2021-01-27
SG11201707789YA (en) 2017-11-29
CN107530344B (zh) 2020-03-17
EP3285772B1 (en) 2019-10-02
PT3285772T (pt) 2020-01-14
US10493074B2 (en) 2019-12-03
ES2763335T3 (es) 2020-05-28
EP3285772A1 (en) 2018-02-28
CA2981631C (en) 2023-02-21
PL3285772T3 (pl) 2020-05-18
WO2016170014A1 (en) 2016-10-27
HUE047162T2 (hu) 2020-04-28
BR112017020591B8 (pt) 2023-05-16
CO2017010573A2 (es) 2018-03-09
CA2981631A1 (en) 2016-10-27
AR105552A1 (es) 2017-10-18

Similar Documents

Publication Publication Date Title
DOP2019000180A (es) INHIBIDORES DE TGFß1 ISOFORMA-ESPECÍFICOS CONTEXTO-PERMISIVOS Y USO DE LOS MISMOS
BR112017020149A2 (pt) derivados de maitansinoide, conjugados dos mesmos e métodos de uso
CL2015003686A1 (es) Derivados de pirrolo[3,2-d]pirimidina para el tratamiento de infecciones víricas y otras enfermedades
BR112017019738A2 (pt) macrociclos peptidomiméticos e usos dos mesmos
BR112018072450A2 (pt) análogo de trifluoroetil quinolina específico para uso no tratamento de apds
SG10201908697XA (en) A pharmaceutical composition for use in the treatment or prevention of a c5-related disease and a method for treating or preventing a c5-related disease
AR100215A1 (es) Conjugados de anticuerpo-fármaco anti-ptk7
WO2015173633A3 (en) Hdl therapy markers
TW201613935A (en) Tricyclic heterocycles as BET protein inhibitors
EP3310375A4 (en) USE OF LOW MOLECULAR WEIGHT HUMAN SERUM ALBUMIN FRACTIONS FOR TREATING DISEASES
BR112015027399A2 (pt) ANTICORPOS ANTI-IGF-1R COM LIGAÇÃO DE FcRn ABOLIDA E SEU USO NO TRATAMENTO DE ENFERMIDADES VASCULARES OCULARES
BR112017015387A2 (pt) composição em gel tópica, método de tratamento de uma infecção da pele, composição em gel oftálmica, e, método de tratamento de uma afecção infecciosa do olho ou pálpebra
BR112017010037A2 (pt) acabamento livre de tensoativo sintético, folha tendo acabamento livre de tensoativo sintético, artigos tendo folha com acabamento livre de tensoativo sintético e métodos relacionados
PH12016501371A1 (en) Pharmaceutical compositions comprising 15-hepe and methods of treating asthma and lung disorders using same
MX2020004411A (es) Anticuerpos anti-cd40 para usarse en el tratamiento del sindrome de sjogren.
BR112018014723A2 (pt) fantasmas bacterianos para o tratamento de câncer
EP3533451A4 (en) APPLICATION OF PAEENIFLORIN-6'-O-BENZENE SULFONATE IN MEDICINE FOR THE TREATMENT OF SJÖGREN SYNDROME
BR112017011685A2 (pt) composições compreendendo 15-hepe e métodos de tratamento ou prevenção da fibrose usando as mesmas
BR112017020591A2 (pt) análogo de trifluoroetila específico para uso no tratamento de síndrome de sjögren
BR112018012126A2 (pt) ?adjuvante, método para prevenir e/ou tratar uma doença autoimune, e, uso de um adjuvante?
IT201700109607A1 (it) Composizione per l'uso nella prevenzione e/o nel trattamento del glaucoma.
BR112018014161A2 (pt) composições biofotônicas para tratar ferimento de pele e tecido mole tendo uma ou ambas as infecções resistentes e não resistentes
IT201700029316A1 (it) Composizione per uso nel trattamento dell'endometriosi e dei sintomi associati all’endometriosi
EP3380092A4 (en) COMPOSITION OF OLIVETOL AND METHOD FOR REDUCING OR INHIBITING THE EFFECT OF TETRAHYDROCANNABINOL IN THE HUMAN BODY
ITUA20162781A1 (it) Kit di medicamenti per l’uso nel trattamento di lesioni dei tessuti tegumentari.

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]

Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS.

B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 20/04/2016, OBSERVADAS AS CONDICOES LEGAIS

B25D Requested change of name of applicant approved

Owner name: UCB BIOPHARMA SRL (BE)